StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

Bio-Path Stock Down 9.7 %

NASDAQ:BPTH opened at $0.81 on Friday. The stock’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $1.57. Bio-Path has a 52-week low of $0.80 and a 52-week high of $12.40.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.38. During the same period last year, the business earned ($10.60) earnings per share. Analysts forecast that Bio-Path will post -6.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.